FTC approves Endo’s $8bn buyout of Par

19-11-2015

FTC approves Endo’s $8bn buyout of Par

ElenaR / Shutterstock.com

The Federal Trade Commission (FTC) has issued a final approval of Endo’s $8 billion acquisition of Par Pharmaceutical, saying it is not anti-competitive.


FTC; Endo; Par Pharmaceutical; anti-competition; ulcers; Federal Trade Commission

LSIPR